Risk factor
Poor trading liquidity
Profitability factor
Very low or no dividends
About
Linc AB operates as a private equity and venture capital firm, dedicating its investments to the pharmaceutical, life sciences, and med-tech sectors across early, mid, and late venture stages. The firm prioritizes investment opportunities within Nordic companies. Its typical investment amounts range from SEK 25 million to SEK 250 million, frequently beginning with a relatively smaller initial capital injection, with subsequent follow-up investments constituting the majority of its financial commitment. Linc AB's headquarters are located in Stockholm, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBI
Target Price
The average target price of LINC.ST is 72.0 and suggests 4.26% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t